InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 FURTHER FINDINGS ON ARTEMIC AS ANTI-INFLAMMATORY AGENT 7 May 2021 4:12PM $0.061 $0.420 risen by 588.52%
$18 Trading Halt 6 May 2021 11:28AM $0.061 $0.420 risen by 588.52%
$18 Pause in Trading 6 May 2021 9:57AM $0.061 $0.420 risen by 588.52%
$18 $1M ORDER FOR ARTEMIC RESCUE FROM SWISS PHARMACAN 4 May 2021 8:55AM $0.059 $0.420 risen by 611.86%
$18 ARTEMIC SUBMITTED TO HEALTH CANADA 28 Apr 2021 12:41PM $0.060 $0.420 risen by 600%
$18 MARCH QUARTERLY ACTIVITY AND CASHFLOW REPORT 27 Apr 2021 8:22AM $0.060 $0.420 risen by 600%
$18 Proposed issue of Securities - MXC 22 Apr 2021 5:55PM $0.062 $0.420 risen by 577.42%
$18 MGC PHARMA TO ACQUIRE MEDICAL RESEARCH COMPANY MEDICANL 22 Apr 2021 9:04AM $0.060 $0.420 risen by 600%
$18 Appendix 2A - Option Conversion 16 Apr 2021 4:55PM $0.064 $0.420 risen by 556.25%
$18 INVESTOR PRESENTATION 9 Apr 2021 10:12AM $0.068 $0.420 risen by 517.65%
$18 Proposed issue of Securities - MXC 9 Apr 2021 8:22AM $0.070 $0.420 risen by 500%
$18 Change of Company Secretary, Perf Rights & Remuneration 9 Apr 2021 8:21AM $0.070 $0.420 risen by 500%
$18 MXC COMPLETES FIRST ARTEMIC ORDER, MARCH QTR RECORD REVENUE 7 Apr 2021 9:34AM $0.061 $0.420 risen by 588.52%
$18 Results of General Meeting 1 Apr 2021 8:21AM $0.062 $0.420 risen by 577.42%
$18 Appendix 2A 24 Mar 2021 7:10PM $0.072 $0.420 risen by 483.33%
$18 Ethics Committee Approval Granted Phase III Clinical Trial 23 Mar 2021 9:03AM $0.075 $0.420 risen by 460%
$18 MGC Pharma General Meeting Information and Webinar 19 Mar 2021 4:19PM $0.077 $0.420 risen by 445.45%
$18 Appendix 2A 9 Mar 2021 7:03PM $0.056 $0.420 risen by 650%
$18 Change of Director's Interest x3 9 Mar 2021 10:27AM $0.056 $0.420 risen by 650%
$18 SwissPharmaCan AG increases initial purchase order 3 Mar 2021 9:31AM $0.080 $0.420 risen by 425%
$18 Half Yearly Report and Accounts 26 Feb 2021 1:31PM $0.091 $0.420 risen by 361.54%
$18 Notice of Meeting and Incentive Share Plan 25 Feb 2021 7:22PM n/a $0.420 n/a
$18 Master Suppy and Distribution Agreement for ArtemiC Rescue 18 Feb 2021 10:25AM $0.080 $0.420 risen by 425%
$18 LSE Dual Listing & Depositary Interest Information 16 Feb 2021 7:09PM $0.078 $0.420 risen by 438.46%
$18 New In-vitro cannabinoid study on Glioblastoma treatment 15 Feb 2021 9:15AM $0.065 $0.420 risen by 546.15%

326 - 350 of 818 results

Page 14 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.